'Fast Money' traders talk GLP-1 manufacturer stocks sinking on uncertainty and price negotiation. These are the most ...

Dr. Kavita Patel joins 'Fast Money' to talk what is next for GLP-1 drug makers. Senior Personal Finance Correspondent Sharon ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

"We see opportunity within our unique snacking portfolio," Tom McGough, co‐chief operating officer with Conagra Brands, told ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...

LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...

What can people eat and drink when taking GLP-1 drugs like Ozempic to help them lose weight? FoodNavigator explores ...